
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$37.40
−$0.32 · -0.85%
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Latest quote
$37.40
−$0.32 · -0.85%
After-hours
$37.40
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Day range
Current $37.40
52-week range
Current $37.40
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
87
Deep Value
Sentiment
41
Mixed
Risk
57
Elevated Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Day range
Current $37.40
52-week range
Current $37.40
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.52B USD | 1.3B USD | 1.02B USD | 977.89M USD | 942.26M USD |
| Cost of goods sold | 1.01B USD | 896.27M USD | 704.59M USD | 679.65M USD | 656.86M USD |
| Gross profit | 511.71M USD | 399.94M USD | 313.09M USD | 298.24M USD | 285.4M USD |
| Selling, general, and administrative | 312.5M USD | 289.48M USD | 259.78M USD | 226.39M USD | 206.41M USD |
| Operating expenses | 312.5M USD | 289.48M USD | 259.78M USD | 226.39M USD | 206.41M USD |
| Interest income | 1.46M USD | 2.62M USD | 4.47M USD | 3.36M USD | 816K USD |
| Interest expense | 47.6M USD | 33.25M USD | 21.97M USD | 17.95M USD | 12.1M USD |
| Depreciation and amortization | 51.51M USD | 45.61M USD | 36.18M USD | 34.01M USD | 32.71M USD |
| Operating income | 198.44M USD | 110.47M USD | 53.32M USD | 71.85M USD | 78.99M USD |
| Net income | 99.72M USD | 48.26M USD | 2.42M USD | 32.61M USD | 49.18M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
$0.48
2025 complete year0.0% since 2021
2026 partial: $0.36
$0.48
2,021
$0.48
2,022
$0.48
2,023
$0.48
2,024
$0.48
2,025
$0.36
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Sep 2, 2026 | $0.12Quarterly | Sep 2, 2026 | Sep 23, 2026 |
Dividend | Jun 3, 2026 | $0.12Quarterly | Jun 3, 2026 | Jun 24, 2026 |
Dividend | Mar 4, 2026 | $0.12Quarterly | Mar 4, 2026 | Mar 25, 2026 |
Dividend | Nov 26, 2025 | $0.12Quarterly | Nov 26, 2025 | Dec 17, 2025 |
Dividend | Sep 3, 2025 | $0.12Quarterly | Sep 3, 2025 | Sep 24, 2025 |
Dividend | Jun 4, 2025 | $0.12Quarterly | Jun 4, 2025 | Jun 25, 2025 |
Ex-dividend Sep 2, 2026
$0.12
Quarterly
Record Sep 2, 2026 · Payment Sep 23, 2026
Ex-dividend Jun 3, 2026
$0.12
Quarterly
Record Jun 3, 2026 · Payment Jun 24, 2026
Ex-dividend Mar 4, 2026
$0.12
Quarterly
Record Mar 4, 2026 · Payment Mar 25, 2026
Ex-dividend Nov 26, 2025
$0.12
Quarterly
Record Nov 26, 2025 · Payment Dec 17, 2025
Ex-dividend Sep 3, 2025
$0.12
Quarterly
Record Sep 3, 2025 · Payment Sep 24, 2025
Ex-dividend Jun 4, 2025
$0.12
Quarterly
Record Jun 4, 2025 · Payment Jun 25, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR47.5M0.05%104.29B USD0.06%$137.31+0.17%
Vanguard Morningstar Total Stock Market ETFVTI24.89M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM21.1M0.03%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF9.25M0.01%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO7.46M0.05%14.25B USD0.24%$353.47-0.53%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM7.43M0.05%16.01B USD0.03%$53.36+0.15%
Dimensional - US Small Cap ETFDFAS6.12M0.02%33.66B USD0.31%$78.10+0.23%
State Street SPDR S&P Pharmaceuticals ETFXPH5.9M1.28%462.1M USD0.35%$63.63+1.14%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P Pharmaceuticals ETFXPHAI-generated and delayed market data for informational and educational purposes only. Not investment advice.